Methods of quantifying frataxin and frataxin fusion proteins
AssigneesLarimar Therapeutics, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Servic
InventorsJoan David Bettoun, Erik Johan Wagner, Xin Xu, Jean-Nicholas Mess, Amy Qiu Wang
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for determining the amount of FXN or FXN fusion protein in a sample, e.g, a tissue sample, by using mass spectrometry.
Claims64
A method for determining the amount of unprocessed frataxin (FXN) fusion protein in a sample, said method comprising determining the amount of a peptide in said sample by using mass spectrometry (MS),
- wherein said peptide comprises the amino acid sequence GGMWTLGR (SEQ ID NO:
- 12);
- and
- wherein said unprocessed FXN fusion protein comprises, from N-terminus to C-terminus, a cell penetrating peptide (CPP);
- a mitochondrial targeting sequence (MTS) comprising SEQ ID NO:
- 3;
- and FXN comprising SEQ ID NO:
- 2.
A method for determining the amount of unprocessed TAT-GG-FXN (SEQ ID NO:
- 11) in a sample, said method comprising determining the amount of at least one peptide in said sample by using MS,
- wherein said at least one peptide is selected from the group consisting of:
- a) a peptide comprising the amino acid sequence SGTLGHPGSLDETTYER (SEQ ID NO:
- 13);
- and
- b) a peptide comprising the amino acid sequence LGGDLGTYVINK (SEQ ID NO:
- 14);
- wherein said method comprises purifying by immunocapture the unprocessed TAT-GG-FXN from said sample prior to MS;
- wherein said immunocapture is carried out using a binding protein comprising an antigen binding domain, wherein said binding protein is capable of binding a TAT protein transduction domain.
A method for determining the amount of FXN in a tissue sample, said method comprising determining the amount of at least one peptide derived from said FXN in said sample by using MS,
- wherein said at least one peptide is selected from the group consisting of:
- a) a peptide comprising the amino acid sequence SGTLGHPGSLDETTYER (SEQ ID NO:
- 13);
- and
- b) a peptide comprising the amino acid sequence LGGDLGTYVINK (SEQ ID NO:
- 14);
- wherein the method is characterized by at least one of the following:
- the method has a precision as measured by % coefficient of variation (% CV) of 20% or less;
- and
- the method has an accuracy of about 80% to about 120%.
A method for determining the amount of FXN in a skin sample, said method comprising determining the amount of at least one peptide derived from said FXN in said skin sample by using MS,
- wherein said at least one peptide is selected from the group consisting of:
- a) a peptide comprising the amino acid sequence GGMWTLGR (SEQ ID NO:
- 12);
- b) a peptide comprising the amino acid sequence SGTLGHPGSLDETTYER (SEQ ID NO:
- 13);
- and
- c) a peptide comprising the amino acid sequence LGGDLGTYVINK (SEQ ID NO:
- 14).
Dependencies are inferred from the claim text.